Effects of Carrilizumab Combined with Chemotherapy on the Therapeutic Efficacy and Intratumoral Microbiota in Patients with Advanced Gastric Cancer
ZHANG Di
DAI Ling
ZHANG Boya
WANG Yingjie
GUO Linna
XU Futian
Abstract：Objective To explore the effects of carrilizumab(SHR-1210)combined with chemotherapy on the thera-peutic efficacy and intratumoral microbiota in patients with advanced gastric cancer.Methods In total,92 patients with ad-vanced gastric cancer treated from April 2020 to May 2021 were selected and divided into research group and control group ac-cording to different treatment methods.The research group received SHR-1210 combined chemotherapy,and the control group received chemotherapy.The therapeutic effect,the levels of serum carcinoembryonic antigen(CEA)and cancer antigen 19-9(CA19-9)before and after treatment,detection rate of intratumoral microbiota after treatment,natural killer(NK)cells and T lymphocyte subsets after treatment,as well as adverse reactions,2-year progression-free survival(PFS)and overall survival(OS)were compared between the two groups.Results After treatment,the total effective rate was 89.1%(41/46)in the research group,which was higher than that[56.5%(26/46)]in the control group(P<0.01).After treatment,the levels of serum CEA,CA19-9,detection rate of intratumoral microbiome,CD8 + and NK cells in the research group were lower than those in the control group(P<0.05,P<0.01).After treatment,the levels of CD4 + and CD4 +/CD8 + in the research group were higher than those in the control group,and the 2-year PFS rate and OS rate were higher than those in the control group(P<0.05,P<0.01).The total incidence of adverse reactions in the research group was lower than that in the control group(P<0.01).Conclusion SHR-1210 combined with chemotherapy can reduce the levels of serum CEA and CA19-9 in patients with advanced gastric cancer,reduce the intratumoral microbiota,greatly improve the safety of treatment,and improve the prognosis,showing significant effects.
Keywords：Gastric neoplasmsLate stageCarrilizumabChemotherapyCarcinoembryonic antigenCancer antigen 19-9Intratumoral microbiotaPrognosis
Publication Date：2023-12-22
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 32-36 )